8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2023

MYCOTOPIA THERAPIES, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-56022	87-0645794
(State of Incorporation)	(Commission File Number)	(IRS Employer ID No.)

100 SE 2nd St, Suite 2000

Miami, FL 33131

(Address of Principal Executive Offices)

(954) 233-3511

(Registrant's Telephone Number including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.02Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. 

In connection with the preparation of the Ehave, Inc. (“Ehave”) financial statements as of December 31, 2022, Ehave’s management, in consultation with its advisors, identified errors made in its previously issued financial statements for the periods ending December 31, 2021 and September 30, 2022. Management determined that these financial statements do not give effect to $288,000 cash compensation and the issuance of a warrant (the “Warrant”) to purchase shares 5% of the fully diluted common stock outstanding of Mycotopia Therapies, Inc. (the “Company”). The cash and Warrant was granted to the Chief Executive Officer of the Ehave and the Company pursuant to his consulting agreement with Mycotopia entered into on November 17, 2021. The Company is unable to quantify the exact amount of the error at this time and has determined it has materially understated its liabilities, operating expenses and additional paid-in capital due to never recording the cash compensation and Warrant issuance. In addition, the Company did not disclose the Warrant issuance and additional compensation in the footnotes to the financial statements then ended. The Company determined the Warrant was never valued and expensed, the cash compensation was never accrued and expensed, and these features were never disclosed. 

As a result of the foregoing, the Company’s management concluded that its previously issued (i) audited balance sheet and consolidated statement of operations for the period ending December 31, 2022, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 30, 2023; and (ii) unaudited interim financial statements for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022, filed on Form 10-Q, should be restated.

The Company has discussed the matters disclosed in this Current Report on Form 8-K with its independent registered public accounting firm, Pinnacle Accountancy Group of Utah and with Ehave Inc.’s independent accounting firm, Turner, Stone & Company, L.L.P.

As a result of this review, we have reviewed the effectiveness of our internal controls over financial reporting. We believe these errors were primarily due to deficiencies pertaining to insufficiently skilled personnel and a lack of human resources within our accounting and finance functions and deficiencies relating to insufficient analysis, documentation and review of the selection and application of GAAP to significant non-routine transactions, including the preparation of financial statement disclosures relating thereto. Our Annual Report on Form 20-F included management’s assessment that, as of the December 31, 2022, evaluation date, our internal controls over financial reporting were not effective. Our restated financial statements on Form 10-K and Form 10-Q will include the necessary updated disclosures regarding our material weaknesses, including the weaknesses identified above.

The discussion of our revised financial results contained in this Current Report on Form 8-K has been prepared by management and represents management’s preliminary assessment of the revised results. These results are subject to change as our independent registered public accounting firm completes its review.

Cautionary Statements Regarding Forward-Looking Statements

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as “believes,” “expects,” “intends,” “plans,” “estimates,” “assumes,” “may,” “should,” “will,” “seeks,” or other similar expressions. Such statements may include, but are not limited to, statements regarding the Company’s intent to restate certain historical financial statements and the timing and impact of the Restatement. These statements are based on current expectations on the date of this Form 8-K and involve a number of risks and uncertainties that may cause actual results to differ significantly. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Mycotopia Therapies, Inc. (the “Registrant”)
	a Nevada corporation
Date: May 2, 2023	By:	/s/Ben Kaplan
		Name: Ben Kaplan
		Title: Chief Executive Officer and Principal Accounting Officer

XML

Document and Entity Information	Apr. 25, 2023
Details
Registrant CIK	0001763329
Registrant Name	MYCOTOPIA THERAPIES, INC.
SEC Form	8-K
Period End date	Apr. 25, 2023
Tax Identification Number (TIN)	87-0645794
Emerging Growth Company	false
Entity Incorporation, State or Country Code	NV
Entity File Number	000-56022
Entity Address, Address Line One	100 SE 2nd St
Entity Address, Address Line Two	Suite 2000
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33131
City Area Code	954
Local Phone Number	233-3511
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Amendment Flag	false